Prescient (ASX: PTX) expands its PTX-200 trial in AML patients
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has taken another step towards advancing...
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has taken another step towards advancing...
Prescient Therapeutics (ASX: PTX) signed off the March quarter with major progress made in its Cell...
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has announced the opening of enrolment...
Cancer results from the mutation of normal cells to tumour cells because of interaction between...
ASX-listed biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) is leaving no stone unturned as it progresses towards...
Cancer is one of the significant causes of death worldwide. As per the World Health...
Biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) engaged in evolving personalized therapies for cancer has released its...
To fight the menace of cancer, there have been categorical and highly efficacious progress in...
A clinical-stage oncology company, Prescient Therapeutics (ASX:PTX) has further strengthened its Scientific Advisory Board (SAB) with the...
One of the leading clinical-stage oncology companies, Prescient Therapeutics Limited (ASX:PTX), has been making its...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.